Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 6/20 | 0.40 |
| ▸ | NOS1 | P29475 | 5/20 | 0.40 |
| ▸ | NOS3 | P29474 | 4/20 | 0.40 |
| ▸ | DDAH1 | O94760 | 4/20 | 0.39 |
| ▸ | NPY4R | P50391 | 5/20 | 0.37 |
| ▸ | NPY1R | P25929 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 2/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1965668 | 0.97 | NPY4R (0.38) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL6130138 | 0.94 | GSR (0.46) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL10876829 | 0.91 | GSR (0.43) | OTCNOS2NOS1NOS3DDAH1 | |
| SCHEMBL7142819 | 0.89 | NPY4R (0.34) | OTCNOS2NOS1NOS3DDAH1 | |
| SCHEMBL2125107 | 0.88 | NPY4R (0.39) | OTCDDAH1NPY4RNPY1RNPY2R | |
| Arginine SCHEMBL333332 | 0.88 | OTC (0.39) | OTCNOS2NOS1NOS3DDAH1 | |
| Tyrosine SCHEMBL11101797 | 0.85 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL6155572 | 0.84 | NPY4R (0.39) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL25212883 | 0.84 | OTC (0.47) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL4586458 | 0.84 | OTC (0.47) | OTCNOS2NOS1NOS3DDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458220-B2 | Single-chain insulin agonists exhibiting high activity at the insulin receptor | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-10-04 | — | — | US | claimed |
| EP-2376521-B1 | AMIDE-BASED INSULIN PRODRUGS | UNIV INDIANA RES & TECH CORP (US) | 2016-04-13 | — | — | EP | claimed |
| US-20160024169-A1 | INSULIN-INCRETIN CONJUGATES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2016-01-28 | — | — | US | claimed |
| US-20150148520-A1 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | UNIV INDIANA RES & TECH CORP (US) | 2015-05-28 | — | — | US | claimed |
| EP-2376520-B1 | INSULIN ANALOGS | UNIV INDIANA RES & TECH CORP (US) | 2014-02-12 | — | — | EP | claimed |
| US-8481485-B2 | Insulin analogs | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-07-09 | — | — | US | claimed |
| US-20110257076-A1 | AMIDE BASED INSULIN PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2011-10-20 | — | — | US | claimed |
| US-20110257091-A1 | INSULIN ANALOGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2011-10-20 | — | — | US | claimed |
| EP-2376520-A1 | INSULIN ANALOGS | Indiana University Research & Technology Corporation (US) | 2011-10-19 | — | — | EP | claimed |
| EP-2376521-A1 | AMIDE-BASED INSULIN PRODRUGS | Indiana University Research and Technology Corporation (US) | 2011-10-19 | — | — | EP | claimed |
| WO-2010080609-A1 | AMIDE-BASED INSULIN PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-07-15 | — | — | WO | claimed |
| WO-2010080606-A1 | INSULIN ANALOGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-07-15 | — | — | WO | claimed |
| US-20230105982-A1 | INSULIN-INCRETIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2023-04-06 | — | — | US | disclosed |
| US-11351268-B2 | FGF21 C-terminal peptide optimization | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-11208451-B2 | Protein and protein conjugate for diabetes treatment, and applications thereof | ADDA BIOTECH INC. | 2021-12-28 | — | — | US | disclosed |
| US-20210388051-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF INSULIN USING SIDE CHAIN ANCHORED LYSINE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S A (GR) | 2021-12-16 | — | — | US | disclosed |
| WO-2011163462-A2 | AMIDE-BASED INSULIN PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110257076-A1 | AMIDE BASED INSULIN PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2011-10-20 | — | — | US | disclosed |
| EP-2376521-A1 | AMIDE-BASED INSULIN PRODRUGS | Indiana University Research and Technology Corporation (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010080609-A1 | AMIDE-BASED INSULIN PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208451-B2 | Protein and protein conjugate for diabetes treatment, and applications thereof | GLP1R, GIPR, IAPP | OTC 3956/4885NOS2 2816/4885NOS1 2239/4885 |
| US-20150148520-A1 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | IGF1R, GPR119, IRS1 | OTC 2737/4885NOS2 2915/4885NOS1 2058/4885 |
| US-20110257076-A1 | AMIDE BASED INSULIN PRODRUGS | IAPP, IDE, DNPEP | OTC 1072/4885NOS2 1352/4885NOS1 1465/4885 |
| US-20230105982-A1 | INSULIN-INCRETIN CONJUGATES | GIPR, GLP1R, GCGR | OTC 3947/4885NOS2 4172/4885NOS1 4617/4885 |
| US-11351268-B2 | FGF21 C-terminal peptide optimization | FGF23, FGFR1, FGFR3 | OTC 2956/4885NOS2 4242/4885NOS1 4553/4885 |
| US-20110257091-A1 | INSULIN ANALOGS | IAPP, GPR119, INSR | OTC 2529/4885NOS2 3548/4885NOS1 3623/4885 |
| US-20210388051-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF INSULIN USING SIDE CHAIN ANCHORED LYSINE | IAPP, INSR, INSRR | OTC 2252/4885NOS2 3590/4885NOS1 3918/4885 |
| US-20160024169-A1 | INSULIN-INCRETIN CONJUGATES | IAPP, GLP1R, INSR | OTC 2887/4885NOS2 4312/4885NOS1 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.